Onset of Labor and Metabolomics (GEM-2)
GEM-2
Feasibility Study to Develop the Analysis of the Metabolome During the Onset of Labor During Pregnancy
1 other identifier
observational
80
1 country
1
Brief Summary
Premature birth is a public health problem and its incidence has recently increased in all developed countries. In Canada, it represented 6.4% of births in 1981 and 7.6% in 2000. In the last decade, the survival rate of premature infants has increased considerably, but neurological vulnerability has not changed. Premature births are the cause of approximately 28% of neonatal mortality in the world and is the major cause of perinatal mortality and morbidity in developed countries. Approximately 75-80% of preterm births are spontaneous preterm birth. This type of premature birth included the preterm labor and premature rupture of membranes before term. The contractile activity represents one of the fundamental properties of the uterus during pregnancy and childbirth. The abnormalities associated with uterine contractions are the cause of pathological conditions with important consequences for the mother and fetus. Metabolomics involves a new technology to investigate small molecules that characterize biochemical pathways of interest. The change in concentration levels of these molecules in various biological samples such as urine and blood in the presence of a disease or a patient can be particularly useful for identifying new biomarkers. The hypothesis of this study is that gestational metabolomes detected in maternal fluids differ according to pathological situations and lead to the initiation of spontaneous labor. The whole research program has two complementary objectives in order to expect a decrease of prematurity: a) better understanding of all the physiological mechanisms leading to prematurity and b) better identification of patients at high risk for a better management of these women.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2009
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2009
CompletedFirst Submitted
Initial submission to the registry
February 18, 2010
CompletedFirst Posted
Study publicly available on registry
February 19, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2017
CompletedMay 12, 2015
May 1, 2015
7.9 years
February 18, 2010
May 11, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
comparison between the metabolic patterns of women before and during labor
one and half year
Secondary Outcomes (3)
The study also looks at the comparison of metabolic patterns in late pregnancy and postpartum.
one and half year
The project will characterize the metabolome in different fluids collected
one and half year
The study will compare the metabolome of women with spontaneous onset of labor with that of women with premature rupture of membranes or induction of labor
one and half year
Study Arms (1)
GEM-2 Cohort
Women who have a low risk pregnancy before onset of labor. Patients included in the study who will be hospitalized with spontaneous labor at term with intact membranes or preterm labor will be included in the study group. Patients with premature rupture of membranes or induction of labor will be analyzed separately.
Eligibility Criteria
Pregnant women between 20-30 weeks of gestation who have a low risk pregnancy.
You may qualify if:
- Women with single pregnancy
- Adults (\> 18 years old)
You may not qualify if:
- Women with a severe congenital fetal malformation
- Fetal death
- Preexisting hypertension (ie before 20 weeks of gestation)
- Anti-phospholipid syndrome
- Lupus,
- Nephropathy, etc.
- Viral infections (HIV or hepatitis)
- Women who want an elective Caesarean section are excluded
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre Hospitalier de l'Université de Sherbrooke
Sherbrooke, Quebec, J1H 5N4, Canada
Biospecimen
Vaginal secretions, whole blood and urine are collected
Study Officials
- PRINCIPAL INVESTIGATOR
Jean-Charles Pasquier, MD, PhD
Centre Hospitalier de l'Université de Sherbrooke
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
February 18, 2010
First Posted
February 19, 2010
Study Start
April 1, 2009
Primary Completion
March 1, 2017
Study Completion
June 1, 2017
Last Updated
May 12, 2015
Record last verified: 2015-05